Revolution Medicines, Inc. Common Stock
RVMD
$144.12
+2.54%
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers, a notoriously difficult-to-treat genetic driver. The company is a key player in the biotechnology sector, distinguished by its proprietary platform for creating small molecules that directly inhibit active RAS variants, positioning it as a potential disruptor in a high-value therapeutic area. The current investor narrative is overwhelmingly driven by the recent positive Phase 3 data for its lead candidate, daraxonrasib, in pancreatic cancer, which demonstrated a doubling of survival, and the subsequent $2.2 billion capital raise to fund its ambitious clinical development plans, creating a debate between transformative potential and near-term shareholder dilution.…
RVMD
Revolution Medicines, Inc. Common Stock
$144.12
Related headlines
Investment Opinion: Should I buy RVMD Today?
Rating: Hold. The core thesis is that while RVMD's clinical breakthrough is legitimate and de-risks the pipeline, the stock's explosive 250% rally and ~$19 billion market cap have largely priced in this success, offering limited near-term upside and high sensitivity to any misstep, making it suitable only for highly risk-tolerant investors.
Supporting evidence includes the stock's proximity to its 52-week high ($155.7), just 13% below that key resistance. Analyst revenue estimates show staggering uncertainty, with a low of ~$993M and a high of ~$15.5B, highlighting the speculative nature of the valuation. The company's financials are typical for its stage but underscore the risk: widening quarterly losses to -$364.9M, negative ROE of -69.35%, and a cash burn of -$913.7M TTM, albeit now offset by the $2.2B capital raise. The unanimous bullish analyst sentiment is a positive, but it is a coincident indicator following the massive price move.
The two biggest risks are clinical/regulatory setbacks for daraxonrasib and valuation compression from current elevated levels. This Hold rating would upgrade to a Buy if the stock experiences a meaningful pullback (e.g., towards the $100-$110 range) on non-fundamental volatility, providing a better risk/reward entry. It would downgrade to a Sell if the next clinical update contains any material negative surprise, QoQ cash burn accelerates unexpectedly beyond projections, or competitive data emerges that threatens daraxonrasib's best-in-class profile. Relative to its own history and the binary nature of its pipeline, the stock is fairly to fully valued, demanding perfection from future catalysts.
Sign up to view all
RVMD 12-Month Price Forecast
RVMD is a high-risk, high-reward binary biotech investment at an inflection point. The transformative Phase 3 data and fortified balance sheet provide a solid foundation, but the market has aggressively repriced the stock, leaving limited near-term margin for error. The neutral stance reflects a belief that the most probable 12-month outcome is consolidation within a wide range as investors await the next set of clinical and regulatory de-risking events. The stance would upgrade to bullish on a pullback to the $110-$120 range without a change in fundamentals, providing a better risk/reward profile. It would turn bearish on any clinical setback or guidance delay, which could trigger a rapid de-rating towards the $90s.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $187.36 and implied upside of +30.0% versus the current price.
Average Target
$187.36
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$115 - $187
Analyst target range
Analyst coverage appears robust, with six firms providing estimates, and institutional ratings data shows a unanimous bullish sentiment with recent actions from ten major firms all being Buys, Outperforms, or Overweights. The consensus recommendation is strongly bullish. While a specific average target price is not provided in the data, the high level of institutional support and the recent wave of positive ratings following the Phase 3 data clearly signal strong analyst conviction in the company's prospects. The estimated revenue range for analysts is exceptionally wide, from a low of ~$993 million to a high of ~$15.5 billion, with an average of ~$4.6 billion. This enormous spread, along with an EPS estimate range from -$0.17 to +$31.25, underscores the extreme uncertainty and binary nature of valuing a pre-commercial biotech. The high target scenario likely assumes successful commercialization and market penetration for daraxonrasib and other pipeline assets, while the low end may reflect more conservative adoption or clinical setbacks. The recent pattern of reiterated bullish ratings by all covering firms in Q1 2026 indicates strengthening conviction following the pivotal trial data.
Bulls vs Bears: RVMD Investment Factors
The bull case for RVMD, driven by transformative Phase 3 data and fortified by a massive capital raise, currently holds stronger evidence, as reflected in the unanimous analyst bullishness and explosive 250% price appreciation. However, the bear case presents formidable counterpoints centered on extreme pre-revenue valuation, heavy cash burn, and recent shareholder dilution. The single most important tension in the investment debate is the binary risk-reward profile: the stock's ~$19 billion valuation fully prices in successful commercialization of daraxonrasib, leaving the share price highly vulnerable to any clinical, regulatory, or competitive setback that could trigger a severe de-rating from current elevated levels.
Bullish
- Phase 3 Data Doubles Survival: The lead candidate, daraxonrasib, demonstrated a doubling of survival in a Phase 3 pancreatic cancer trial, a notoriously difficult-to-treat indication. This transformative clinical result is the primary driver of the stock's 250% 1-year gain and underpins the entire investment thesis for a multi-billion dollar market opportunity.
- Massive $2.2B Capital Raise: The recent $2.2 billion capital raise de-risks the ambitious clinical pipeline by providing a multi-year financial runway. This eliminates near-term financing concerns, allowing the company to aggressively advance its RAS oncology programs without immediate dilution pressure.
- Unanimous Analyst Conviction: Analyst sentiment is overwhelmingly bullish, with recent actions from ten major firms all being Buys or Overweights. This strong institutional support, following the pivotal trial data, signals high conviction in the company's path to commercialization and validates the clinical breakthrough.
- Explosive Technical Momentum: The stock exhibits powerful momentum, up 43.5% in one month and 250.7% over one year, massively outperforming the SPY. Trading at 87% of its 52-week high ($155.7), the price action reflects sustained investor optimism and a high-velocity repricing of the pipeline's value.
Bearish
- Pre-Revenue with Heavy Losses: The company is deeply unprofitable, reporting a Q4 2025 net loss of -$364.9 million and an EPS of -$1.90, with zero product revenue. Losses are widening sequentially as R&D spending ramps, burning -$913.7 million in TTM free cash flow, highlighting the cash-intensive nature of clinical development.
- Extreme Valuation & Binary Risk: With a ~$19.1 billion market cap and no revenue, valuation is purely speculative on future pipeline success. Analyst revenue estimates range from ~$993M to ~$15.5B, illustrating extreme uncertainty. The stock is priced for perfection near its 52-week high, leaving no margin for clinical or regulatory setbacks.
- Significant Shareholder Dilution: The $2.2 billion capital raise, while strengthening the balance sheet, came with immediate and substantial shareholder dilution. This dilutive financing event tempers the per-share value of the pipeline's future potential for existing investors.
- High Short Interest: A short ratio of 7.98 indicates significant bearish bets against the stock. This reflects a cohort of investors who believe the current valuation is unsustainable or that clinical/regulatory risks are being underestimated, creating potential for a sharp squeeze or amplified downside on negative news.
RVMD Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +250.70%, significantly outperforming the SPY's +30.59%. As of the latest close at $135.30, the price is trading near the top of its 52-week range (34.0 - 155.7), specifically at approximately 87% of the range, indicating strong momentum but also proximity to a key technical resistance level. This positioning suggests the stock is priced for perfection, with any negative catalyst potentially triggering a sharp pullback from overextended levels. Recent momentum has been explosive, with a 1-month surge of +43.49% and a 3-month gain of +15.02%, both massively outpacing the broader market. This short-term acceleration, particularly the sharp rally from mid-April, diverges from a period of consolidation earlier in Q1 and is directly attributable to the positive Phase 3 data announcement. The divergence from the market (relative strength of +34.79% over 1 month) underscores the stock-specific, binary nature of the catalyst driving this move. Key technical support is anchored at the 52-week low of $34.0, while immediate resistance sits at the 52-week high of $155.7. A decisive breakout above $155.7 would signal a continuation of the bullish trend, while a failure and reversal could see a test of lower support levels established during the Q1 consolidation around $92-$96. The stock's beta of 1.01 indicates its volatility is roughly in line with the market, which is notable given its clinical-stage status; however, its recent price action demonstrates event-driven volatility that far exceeds its beta reading.
Beta
1.01
1.01x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$34-$156
Price range past year
Annual Return
+256.9%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | +48.2% | +10.5% |
| 3m | +48.7% | +3.9% |
| 6m | +144.9% | +5.4% |
| 1y | +256.9% | +29.6% |
| ytd | +82.4% | +5.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
As a pre-revenue clinical-stage biotech, Revolution Medicines reported zero revenue for the latest quarter (Q4 2025), with its only income stream being a modest $7.0 million in collaboration revenue over an unspecified period. The company's financials are entirely defined by its heavy investment in research and development, with no commercial sales to analyze for growth trajectory. The investment case is purely predicated on the future potential of its pipeline, not current revenue generation. The company is deeply unprofitable, reporting a net income of -$364.9 million for Q4 2025 and an EPS of -$1.90. Gross profit was negative at -$4.7 million, and all margin metrics (gross, operating, net) are at 0% or negative, which is typical for a company in this stage. Losses have been widening sequentially, with Q4's net loss of -$364.9 million greater than Q3's -$305.2 million and Q2's -$247.8 million, reflecting an aggressive ramp in R&D spending to advance its clinical programs. The balance sheet was recently fortified by a massive $2.2 billion capital raise, which should provide a multi-year runway. Prior to this, liquidity was strong with a current ratio of 7.14 and a quick ratio of 7.14 as of the last report. The company burns significant cash, with free cash flow (TTM) at -$913.7 million and operating cash flow for Q4 alone at -$274.2 million. The debt-to-equity ratio is a minimal 0.097, indicating a low reliance on debt financing, but the negative ROE of -69.35% and ROA of -30.08% highlight the heavy burn on shareholder equity as the company funds its development.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-913731000.0B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio. However, with zero revenue, the trailing PS ratio is 0, rendering it meaningless. In the absence of sales, valuation for a clinical-stage biotech like RVMD is primarily driven by the net present value of its pipeline, market potential, and milestone catalysts, rather than traditional multiples. A peer comparison using standard valuation multiples is not feasible as the company lacks the fundamental metrics (revenue, earnings) required for such an analysis. The stock's $15.1 billion market cap reflects a high-conviction bet on the success and commercial potential of its RAS oncology pipeline, particularly following the positive Phase 3 data. Any premium or discount to sector averages is purely speculative and not quantifiable with the provided data. Historical context shows the stock's own valuation has been volatile and tied to clinical updates. The provided historical PE ratios are all negative due to consistent losses. The current market cap of ~$19.1 billion (from company identity data) represents a significant expansion from historical levels, placing it near its own historical highs in terms of absolute market value. This reflects the market's incorporation of the recent positive clinical data and reduced financing risk post-capital raise into its valuation, pricing in optimistic expectations for regulatory approval and future commercialization.
PE
-13.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -22x~-6x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute. As a pre-revenue clinical-stage biotech, RVMD burns cash at an accelerating rate, with a Q4 2025 net loss of -$364.9 million and TTM free cash flow of -$913.7 million. While the $2.2 billion raise provides a long runway, the widening quarterly losses (from -$247.8M in Q2 to -$364.9M in Q4) indicate R&D spending is ramping aggressively. The company has 100% revenue concentration risk on its pipeline, with no commercial sales to cushion any development delays. Profitability metrics are all negative, including an ROE of -69.35%, meaning shareholder equity is being consumed to fund operations.
Market & Competitive Risks are significant. The stock trades at 87% of its 52-week high ($155.7), following a 250% yearly surge, indicating it is priced for flawless execution. Any disappointment could trigger severe valuation compression from these extended levels. The RAS oncology space is highly competitive and scientifically challenging; while the Phase 3 data is strong, rival programs from larger pharmaceutical companies pose a long-term commercial threat. The stock's beta of 1.01 suggests market-correlated volatility, but its recent event-driven price action shows it possesses idiosyncratic, binary-event risk far exceeding its beta.
Worst-Case Scenario involves a material clinical or regulatory setback for daraxonrasib, such as an unexpected safety signal in ongoing trials or a Complete Response Letter from the FDA. This could shatter the current valuation narrative, which is built entirely on future commercial success. Coupled with the high short interest (ratio 7.98), such news could trigger a rapid unwind of momentum positions. A realistic downside could see the stock re-test its 52-week low of $34.00, representing a potential loss of approximately -75% from the current price of $135.30. A more moderate bear case, incorporating pipeline value beyond the lead asset, might see a pullback to the Q1 2026 consolidation support around $92-$96, implying a -30% to -32% decline.
FAQ
The key risks are, in order of severity: 1) Clinical/Regulatory Risk: Any setback for lead candidate daraxonrasib in ongoing trials or during FDA review could crater the stock. 2) Valuation & Dilution Risk: The stock is priced for perfection after a 250% rally, and the recent $2.2B capital raise caused immediate shareholder dilution. 3) Financial Risk: The company burns cash aggressively, with a TTM free cash flow of -$913.7M and widening quarterly losses, though the recent raise mitigates near-term concerns. 4) Competitive Risk: The RAS oncology field is competitive, and larger rivals could develop superior or faster-to-market therapies.
The 12-month forecast is highly scenario-dependent. Our base case (50% probability) sees the stock consolidating between $130 and $160 as investors await regulatory milestones, with an average target aligned with current elevated levels. The bull case (25% probability), targeting $175-$200, requires flawless execution towards approval and upward sales revisions. The bear case (25% probability), targeting $70-$100, is triggered by a clinical or regulatory hiccup. The most likely outcome is the base case, as the massive positive catalyst (Phase 3 data) has already occurred, and the next set of catalysts (regulatory filing) is already anticipated.
RVMD's valuation is speculative and not quantifiable by traditional metrics like P/E or P/S due to a lack of revenue. Its $19.1 billion market cap reflects a high-conviction bet on the future commercial success of daraxonrasib. Compared to its own history, the stock is at an elevated level following the Phase 3 catalyst. The extreme range in analyst revenue estimates ($993M to ~$15.5B) underscores that valuation is a function of probability-weighted future sales, not current fundamentals. At current levels, the market is paying a premium that implies a high probability of success and robust peak sales, leaving little room for error.
RVMD is a good buy only for investors with a very high risk tolerance and a long-term investment horizon who are comfortable with binary, clinical-stage biotech volatility. The positive Phase 3 data is a major de-risking event, and the $2.2 billion capital raise provides ample runway. However, the stock has already surged 250% in a year to trade near its 52-week high, meaning much of this success is priced in. The potential upside remains significant if commercialization is successful, but the downside risk to the 52-week low of $34 (-75%) is severe if the pipeline falters. It is not suitable for conservative investors.
RVMD is strictly a long-term investment for those willing to hold through volatility until commercial milestones are achieved, typically a 3-5 year horizon. The company is pre-revenue, and the path to profitability depends on successful drug approval and launch, which is years away. The stock's high beta (1.01) and event-driven nature make it unsuitable for short-term trading, as prices can gap dramatically on clinical news. There is no dividend. Given the binary nature of the catalysts, a minimum holding period should extend through the next major de-risking event, such as regulatory submission acceptance and/or approval decision.
